Employing Parasite Against Cancer: A Lesson From the Canine Tapeworm Echinococcus Granulocus

Guan Wang, Xiaoqin Zhang, Xiao Wang, Shun Lu, Jun Yin, Jinxin ZhangFrontiers in Pharmacology 2019 · DOI

Abstract

Cystic echinococcosis (CE), a devastating zoonotic condition caused by the tapeworm Echinococcus granulosus, remains a significant public health problem worldwide. However, after a negative correlation between solid tumors and CE was incidentally discovered, accumulating evidence suggests that this parasite may induce anticancer effects through activating host immune responses and secreting molecules with anticancer potential. This review explores the evidence supporting the anticancer effect of E. granulosus, its underlying mechanisms, and possible implications for immunotherapy.

Introduction

Despite the success of immune checkpoint inhibitors (ICIs), many cancer patients do not respond to current immunotherapies, and those who do often face severe immune-related side effects. There is a critical need for novel strategies that can either boost the immunogenicity of "cold" tumors or provide alternative pathways for tumor suppression.

The authors investigate an epidemiological curiosity: a negative correlation between solid tumors and cystic echinococcosis (CE), the disease caused by E. granulosus. This paper synthesizes decades of research to understand how a parasite—typically viewed only as a pathogen—might actually provide a blueprint for the next generation of cancer vaccines and therapeutics.

Methodology

This review evaluates a broad spectrum of existing research, including:

  • Epidemiological Studies: Analyzing clinical data from regions where CE is endemic to identify correlations between parasite infection and cancer incidence.
  • In Vitro Assays: Examining the effects of hydatid fluid and parasite-secreted molecules on various cancer cell lines (e.g., HeLa, WEHI-164 fibrosarcoma).
  • In Vivo Animal Models: Reviewing studies where mice or rats were immunized with parasite antigens or co-infected to observe tumor regression in melanoma, colon, and breast cancer models.

Mechanisms of Anticancer Activity

The interaction between E. granulosus and the host involves complex molecular signaling that inadvertently targets malignant cells through both direct and indirect pathways.

Direct Inhibition via Protease Blockade

The parasite secretes EgKI-1, a Kunitz-type protease inhibitor. This molecule potently inhibits neutrophil elastase, an enzyme that tumors often hijack to facilitate metastasis. By disrupting the cell cycle and inducing apoptosis, EgKI-1 acts as a direct anticancer agent.

Molecular Mimicry and Immune Activation

E. granulosus and many human carcinomas share specific carbohydrate structures, particularly mucin-type O-glycans (like the Tn and sTn antigens). Because the immune system mounts a vigorous response against the parasite, it may inadvertently develop cross-reactive immunity against tumor cells displaying these same "foreign" markers.

Potential mechanisms in the acute stage, where EgKI-1 disrupts the cell cycle and mucin-type O-glycans activate Th1-polarized immunity.

The Th1/Th2 Balance

The timing and stage of infection are critical. A Th1-polarized immune response (typically seen during the acute stage of infection or when a cyst ruptures) is protective against cancer. Conversely, the Th2 response associated with chronic cyst growth may be less effective or even counterproductive.

Antigen B (AgB) Potential

Another major parasite molecule, AgB, also inhibits neutrophil chemotaxis and elastase, potentially reducing the inflammatory environment that tumors need to thrive.

Mechanisms in the chronic stage, highlighting how the release of cyst contents can trigger innate immunity and convert Th2 responses back to protective Th1 responses.

Key Results

  • Tumor Regression: In mouse models, vaccination with hydatid fluid led to significant regression of experimental CT26 colon cancer.
  • Selective Cytotoxicity: Sera from patients with hydatid disease were found to be cytotoxic to lung cancer cell lines while leaving healthy fibroblast cells unharmed.
  • Metastasis Inhibition: EgKI-1 was shown to restrict the growth and migration of triple-negative breast cancer in BABL/c mice, likely through its potent inhibition of neutrophil elastase.
  • High Homology: Researchers found 60% homology between the parasite's heat shock protein 70 (HSP70) and "mortalin," a protein found in CT26 colon cancer cells, further supporting the theory of immunological cross-reactivity.

Limitations and Future Directions

Translating these findings into clinical practice requires overcoming several hurdles:

  • Species Differences: Most mechanistic data comes from murine models; human immune systems may react differently to these parasite antigens.
  • Safety Concerns: E. granulosus is a dangerous pathogen. Future work must focus on isolating specific, non-pathogenic recombinant proteins (like EgKI-1) rather than using crude parasite extracts.
  • Th1/Th2 Control: Precisely controlling the host's immune polarization is difficult. If a vaccine inadvertently triggers a Th2-dominant response, it could theoretically facilitate rather than inhibit cancer progression.
  • Identification of "ES" Products: More research is needed to fully characterize the "excretory/secretory" (ES) molecules the parasite uses to modulate its environment, as these likely hold the most therapeutic potential.

Summary updated

Abstract

Cystic echinococcosis (CE), a devastating zoonotic condition caused by the tapeworm <i>Echinococcus granulosus</i>, remain a significant public health problem worldwide. However, after a negative correlation between solid tumor and CE has been incidentally discovered, accumulating evidence have suggested that this parasite may induce anticancer effect through activating host immune response and secreting molecules with anticancer potential, which may provide some new understanding for immunotherapy. This article will review the evidence supporting the anticancer effect of <i>E. granulosus</i> and its underlying mechanisms and discuss the possible implications in immunotherapy.
BibTeX
@inproceedings{wang2019employing,
  author = {Guan Wang and Xiaoqin Zhang and Xiao Wang and Shun Lu and Jun Yin and Jinxin Zhang},
  title = {{Employing Parasite Against Cancer: A Lesson From the Canine Tapeworm Echinococcus Granulocus}},
  booktitle = {Frontiers in Pharmacology},
  year = {2019},
  doi = {10.3389/fphar.2019.01137},
}
Figure